Related Experiment Video

Updated: May 23, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

[Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story]

José Ramón Azanza Perea1, José Barberán

  • 1José Ramón Azanza Perea, Servicio de Farmacología Clínica, Clínica Universidad de Navarra, Avenida Pío XII s/n - 31008 Pamplona, Spain. jrazanza@unav.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|April 11, 2012
PubMed

Insights

Liposomal amphotericin B remains a leading treatment for systemic fungal infections due to its efficacy and improved safety profile. Its stable formulation minimizes toxicity, offering a better therapeutic option compared to other amphotericin B versions.

Area of Science:

  • Mycology
  • Pharmacology
  • Drug Delivery Systems

Context:

  • Systemic fungal infections pose significant health risks.
  • Amphotericin B is a cornerstone antifungal agent.
  • Liposomal formulations aim to improve drug safety and efficacy.

Purpose:

  • To review the therapeutic role and characteristics of liposomal amphotericin B.
  • To highlight its pharmacokinetic and safety advantages.
  • To explain its mechanism of action.

Summary:

  • Liposomal amphotericin B is a stable formulation with minimal free drug (<1%).
  • It exhibits reduced nephrotoxicity and improved tolerability compared to other amphotericin B formulations.
  • High plasma concentrations, low distribution volume, and prolonged half-life characterize its pharmacokinetics.
  • The liposome targets ergosterol in fungal membranes, releasing amphotericin B for antifungal effect.

Impact:

  • Liposomal amphotericin B offers a superior safety and tolerability profile for treating systemic fungal infections.
  • Its pharmacokinetic properties support sustained therapeutic drug levels.
  • This formulation represents a significant advancement in antifungal therapy, reducing treatment-related adverse events.

More Related Videos

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pore Transport and Ion-Pair Transport01:17

Pore Transport and Ion-Pair Transport

Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited  but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...